. 2020 Feb 25;10:212. doi: 10.3389/fonc.2020.00212

Table 5.

GEMMs for OSCC.

Mouse strains	Brief methods	Tumor formation/ conclusions	References
L2D1⁺/p53^+/− and L2D1⁺/p53^−/− mice	The Epstein-Barr virus ED-L2 promoter (L2) was used to generate the L2-cyclin D1 (L2D1⁺) mouse, which was crossed L2D1⁺ mice with p53^+/− and p53^−/− mice	Both models developed invasive oral-esophageal SCC by 6 months	(181)
LSL-Kras ^G12D; K5 or K14-CrePR1	The Kras^G12D oncogene driven by the K5 or K14 promoter was distributed under the control of Cre recombinase fused to a mutant of the human progesterone receptor	Administration of RU486 for 16–24 weeks induced the overexpression of oncogenic K-ras^G12D in the oral epithelium of mice and resulted in the development of squamous papillomas in the oral cavity.	(185)
Tgfbr1/Pten 2cKO mice	The Tgfbr1^flox/flox mice and Pten^flox/flox mice crossed with mice driven by K14-CreER^tam	After tamoxifen (tam) induction for 10 weeks, the Tgfbr1/Pten 2cKO mice developed cancer and precancerous lesions in the oral epithelium.	(180)
p53^R172H; K5-CrePR1 and p53^flox/flox; K5-CrePR1 mice	The Neo-p53^R172H and p53^flox/flox mice crossed with K5-CrePR1 transgenic mice	By 15–16 months, p53^R172H; K5-CrePR1 (16%) and p53^flox/flox; K5-CrePR1 (25%) mice developed OSCC	(182)
LSL-Kras; iHPV-Luc; K14-CreER^tam mice (KHR mice) and LSL-Kras; K14-CreER^tam mice (KR mice)	The iHPV-Luc transgenic mice were established by knocking-in HPV16 E6E7 and a luciferase reporter on an FVB background. K14-CreER^tam mice were backcrossed to the FVB background and then bred with iHPV-Luc mice to generate K14-CreER^tam × iHPV-Luc (KH) mice. After that, KH mice were bred with LSL-Kras mice to produce KHR or KR mice.	Tamoxifen induced oral tumors in KR and KHR mice and the bioluminescence signal of KHR mice maximized 74.8 times higher than that of untreated mice.	(197)
HPV16 E7iresE6; PIK3CA^E545K; KRT14-CreER^tam mice	Combined Rosa26-LSL-E7iresE6 and mutant PIK3CA (Rosa26-LSL-PIK3CA^E545K) under the control of KRT14-CreER^tam using intra-lingual tamoxifen delivery method	After the administration of tamoxifen for 6–8 weeks, oropharyngeal tumors developed with about 40% penetrance (1–2 tumors/tongue)	(198)